BIOMAT Database Logo BIOMAT Database Logo

Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. 1996

W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Department of Pathology, University of California, Irvine 92697-4800, USA. ewrobine@uci.edu

Integration of a cDNA copy of the human immunodeficiency virus (HIV) genome is mediated by an HIV-1-encoded enzyme, integrase (IN), and is required for productive infection of CD4+ lymphocytes. It had been shown that 3,5-dicaffeoylquinic acid and two analogues were potent and selective inhibitors of HIV-1 IN in vitro. To determine whether the inhibition of IN by dicaffeoylquinic acids was limited to the 3,5 substitution, 3,4-, 4,5-, and 1,5-dicaffeoylquinic acids were tested for inhibition of HIV-1 replication in tissue culture and inhibition of HIV-1 IN in vitro. All of the dicaffeoylquinic acids were found to inhibit HIV-1 replication at concentrations ranging from 1 to 6 microM in T cell lines, whereas their toxic concentrations in the same cell lines were > 120 microM. In addition, the compounds inhibited HIV-1 IN in vitro at submicromolar concentrations. Molecular modeling of these ligands with the core catalytic domain of IN indicated an energetically favorable reaction, with the most potent inhibitors filling a groove within the predicted catalytic site of IN. The calculated change in internal free energy of the ligand/IN complex correlated with the ability of the compounds to inhibit HIV-1 IN in vitro. These results indicate that the dicaffeoylquinic acids as a class are potent and selective inhibitors of HIV-1 IN and form important lead compounds for HIV drug discovery.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D002726 Chlorogenic Acid A naturally occurring phenolic acid which is a carcinogenic inhibitor. It has also been shown to prevent paraquat-induced oxidative stress in rats. (From J Chromatogr A 1996;741(2):223-31; Biosci Biotechnol Biochem 1996;60(5):765-68). 3-Caffeoylquinic Acid,3 Caffeoylquinic Acid,Acid, 3-Caffeoylquinic,Acid, Chlorogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.
January 1998, Antimicrobial agents and chemotherapy,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase.
February 2005, Journal of virology,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Inhibitors of human immunodeficiency virus integrase.
March 1993, Proceedings of the National Academy of Sciences of the United States of America,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Inhibitors of human immunodeficiency virus integrase.
January 1999, Advances in virus research,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase.
May 1997, Journal of virology,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant.
December 1996, FEBS letters,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
February 1999, Journal of medicinal chemistry,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Inhibition of human immunodeficiency virus integrase by bis-catechols.
February 1995, Antimicrobial agents and chemotherapy,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
August 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
W E Robinson, and M Cordeiro, and S Abdel-Malek, and Q Jia, and S A Chow, and M G Reinecke, and W M Mitchell
Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles.
May 2020, ACS medicinal chemistry letters,
Copied contents to your clipboard!